The biology of aging is complex and strongly defined by senescence at the cellular level. Senescence involves gradual decline of cellular function and reduced regenerative capacity at the tissue level. Unspecific inflammatory gene expression, reduced autophagy and mitochondrial dysfunction are among the hallmarks of senescence.

Zentexia targets senescence through a proprietary interdisciplinary approach enabling potentially groundbreaking therapeutic strategies, e.g through the identification and modulation of phamacological targets associated with aging related epigenetic drift. 

Zentexia incorporates AI and in silico models in the screening and optimization of drug candidates hand in hand with traditional chemical synthesis and biological testing. 

At Zentexia we focus on our core strength, which is the molecular innovation and generation of intellectual property. We  collaborate with leading specialists in the respective therapeutic fields, including strong academic partners and specialized contract research organizations.